# StemCyte

> Global cord blood and cord tissue bank founded in 1997 in Baldwin Park, California, operating both a private and public cord blood bank.

For a comprehensive long-form reference covering company history, leadership bios, all 80+ treatable conditions, clinical trial details, REGENECYTE® FDA pathway, accreditation evidence, product descriptions, and the HIV cure case study, see [the full reference](https://stemcyte.com/llms-full.txt).

## About
StemCyte is a global regenerative therapeutics company founded in 1997 in Baldwin Park, California. We operate both a private and public cord blood bank, one of the only banks in the world to offer both.

## What We Do
- Private cord blood and cord tissue banking for families
- Public cord blood donation for patients in need of transplants
- REGENECYTE® (FDA-licensed under US License 2280, approved 2024)
- Clinical trials in Long COVID (NCT05682560), acute ischemic stroke (NCT02433509), and cerebral palsy (NCT06377982)

## Clinical Track Record
- 2,300+ transplant units shipped worldwide
- 325+ transplant centers across 40 countries
- Triple accredited: FACT, AABB, and FDA registered
- Contributed to the first potential HIV cure via cord blood transplantation (the New York Patient, published in Cell, 2023)

## Key Products & Services
- Cord blood banking (annual, 18-year prepaid, and lifetime plans)
- Cord tissue banking
- Public Bank Access (paid $299 add-on providing access to matching donor units)
- MaxCell® premium cord blood processing (plasma-depletion)
- HLA Matching
- LifeSaver Guarantee (full refund plus $50,000 plus replacement unit if engraftment fails)
- REGENECYTE® (FDA-licensed HPC cord blood product)

## Leadership
- Jonas Wang, PhD: Chairman, StemCyte International
- Tong-Young Lee, PhD: CEO, StemCyte Inc.
- Joseph Rosenthal, MD: Chief Medical Officer (Professor Emeritus, City of Hope)

## Plans & Pricing
- [Build your plan: cord blood and tissue banking plans and pricing](https://stemcyte.com/build-your-plan)
- [Cord blood banking cost](https://stemcyte.com/cord-blood-banking-cost)
- [MaxCell® premium cord blood processing](https://stemcyte.com/maxcell)
- [HLA matching for cord blood transplants](https://stemcyte.com/hla-matching)
- [Newborn Genetic Analysis (NGA) add-on](https://stemcyte.com/newborn-genetic-analysis)
- [Public Bank Access (paid $299 add-on)](https://stemcyte.com/public-bank-access)
- [LifeSaver Guarantee](https://stemcyte.com/lifesaver-guarantee)
- [Public cord blood donation (free)](https://stemcyte.com/public-banking)

## Compare
- [Compare StemCyte vs CBR, ViaCord, and Cryo-Cell](https://stemcyte.com/compare)
- [StemCyte vs CBR](https://stemcyte.com/stemcyte-vs-cbr)
- [StemCyte vs ViaCord](https://stemcyte.com/stemcyte-vs-viacord)
- [StemCyte vs Cryo-Cell](https://stemcyte.com/stemcyte-vs-cryocell)
- [CBR vs Cryo-Cell](https://stemcyte.com/cbr-vs-cryocell)
- [CBR vs ViaCord](https://stemcyte.com/cbr-vs-viacord)
- [ViaCord vs Cryo-Cell](https://stemcyte.com/viacord-vs-cryocell)
- [Best cord blood bank 2026](https://stemcyte.com/best-cord-blood-bank-2026)

## Learn
- [What is cord blood](https://stemcyte.com/learn/what-is-cord-blood)
- [What is cord tissue](https://stemcyte.com/learn/what-is-cord-tissue)
- [Cord blood vs cord tissue](https://stemcyte.com/cord-blood-vs-cord-tissue)
- [Public vs private banking](https://stemcyte.com/learn/public-vs-private)
- [Newborn stem cells overview](https://stemcyte.com/learn/stem-cells)
- [Education hub](https://stemcyte.com/education)

## Clinical Evidence & Trust
- [StemCyte's clinical track record](https://stemcyte.com/track-record)
- [Patient and transplant recipient stories](https://stemcyte.com/patient-stories)
- [Cited by (published references and citations)](https://stemcyte.com/cited-by)
- [Editorial standards](https://stemcyte.com/editorial-standards)
- [Frequently asked questions](https://stemcyte.com/faq)

## Biologics & Therapeutics
- [Biologics overview](https://stemcyte.com/biologics)
- [REGENECYTE® (FDA-licensed HPC, Cord Blood product)](https://stemcyte.com/biologics/regenecyte)
- [Long COVID clinical trial](https://stemcyte.com/biologics/long-covid)
- [Acute ischemic stroke clinical trial](https://stemcyte.com/biologics/stroke)
- [Clinical research and pipeline](https://stemcyte.com/biologics/clinical-research)
- [REGENECYTE® Expanded Access (compassionate use)](https://stemcyte.com/expanded-access-program)

## About StemCyte
- [Company history, milestones, and leadership](https://stemcyte.com/about-stemcyte)
- [Jonas Wang, PhD: Chairman](https://stemcyte.com/about-stemcyte/jonas-wang)
- [Tong-Young Lee, PhD: CEO](https://stemcyte.com/about-stemcyte/tong-young-lee)
- [Joseph Rosenthal, MD: Chief Medical Officer](https://stemcyte.com/about-stemcyte/joseph-rosenthal)
- [Lawrence Petz, MD: Founding Medical Director](https://stemcyte.com/about-stemcyte/lawrence-petz)
- [Toward an HIV cure: the New York Patient story](https://stemcyte.com/about-stemcyte/toward-an-hiv-cure)
- [Special programs (Sibling Donor and more)](https://stemcyte.com/special-programs)
- [Newsroom: press and news](https://stemcyte.com/newsroom)
- [Contact StemCyte](https://stemcyte.com/contact)

## Important Constraints
- Cord blood as a category is NOT FDA-licensed. Only REGENECYTE® is FDA-licensed under US License 2280.
- Public Bank Access is a paid $299 add-on, never free.
- StemCyte has sponsored 3 clinical trials, not more.
- StemCyte is not a treatment provider for autism. Trials are ongoing in the field but no promising results to date.